Leadership Changes in H. Lundbeck A/S as Dorothea Wenzel Steps Down
H. Lundbeck A/S is set for a noteworthy transition in its Board of Directors as current Chair Dorothea Wenzel prepares to step down. This change will take effect in alignment with the upcoming Annual General Meeting (AGM) slated for 2027. Wenzel has been a significant figure at Lundbeck since joining the Board in 2021, playing an instrumental role as a member of the Audit Committee before her elevation to Chair in March 2025.
The announcement of this leadership shift coincides with Lundbeck’s commitment to advancing its Focused Innovator strategy. This initiative is critical as the company aims to harness the momentum achieved in its commercial performance, bolster its product pipeline, and establish a robust foundation for future growth. As Lundbeck enters the next phase of this strategy, the focus will be on translating previous successes into sustainable long-term growth.
Lars Fruergaard Jørgensen, who will take over from Wenzel, is a seasoned pharmaceutical executive with over three decades of extensive experience within the healthcare sector. Having served as President and CEO of Novo Nordisk from 2017 to 2025, Jørgensen led the company through a period marked by significant expansion and strategic transformation. His leadership in global diabetes care and weight management has positioned him as a key player in the industry.
Effective November 10, 2026, Jørgensen will begin serving on Lundbeck's Board as an observer until formally elected during the AGM in 2027, pending shareholder approval. His vast experience encompasses global pharmaceutical strategy, innovation, and the commercialization of health solutions, making him a fitting choice for Lundbeck’s upcoming endeavors.
Lene Skole, Vice Chair of the Board, expressed gratitude towards Wenzel for her dedication, stating, "Dorothea's leadership has been pivotal during our transformative phase, including the recruitment of our new CEO in 2023 and the initiation of our Focused Innovator strategy. The progress Lundbeck has achieved places us in a much stronger position than just a few years prior, and as we look ahead, continuity in leadership is essential."
In her farewell remarks, Wenzel identified this transition as a timely decision as Lundbeck is positioned for growth. She remarked on the significant advancements made under her tenure, underscoring her pride in the Board’s collaborative efforts to fortify the company’s market standing. "It has been an honor and a privilege to serve at Lundbeck. As we gear up for the next phase, I am confident in the company’s direction and its capacity to build on the strong foundation we have established."
Looking forward, Jørgensen is optimistic about stepping into the Chair position, highlighting Lundbeck’s commitment to brain health paired with a robust business model and promising product pipeline. He shared his enthusiasm for working alongside the Board and executive leadership to further support Lundbeck’s aspirations, benefiting patients, employees, and shareholders alike.
As the 2027 AGM approaches, the nominated candidates for Board membership will be formally announced. Lundbeck is enthusiastic about its future under new leadership, striving to capitalize on its achievements while committed to enhancing global brain health solutions.
In sum, this leadership transition not only signals a continuity of vision but also a renewed commitment to Lundbeck’s strategic objectives and focus on improving lives impacted by neurological and psychiatric disorders. The company remains firmly dedicated to evolving its research, innovating care solutions, and enhancing health equity, with the aim to bring forth lasting value for all stakeholders involved.
The announcement of this leadership shift coincides with Lundbeck’s commitment to advancing its Focused Innovator strategy. This initiative is critical as the company aims to harness the momentum achieved in its commercial performance, bolster its product pipeline, and establish a robust foundation for future growth. As Lundbeck enters the next phase of this strategy, the focus will be on translating previous successes into sustainable long-term growth.
Lars Fruergaard Jørgensen, who will take over from Wenzel, is a seasoned pharmaceutical executive with over three decades of extensive experience within the healthcare sector. Having served as President and CEO of Novo Nordisk from 2017 to 2025, Jørgensen led the company through a period marked by significant expansion and strategic transformation. His leadership in global diabetes care and weight management has positioned him as a key player in the industry.
Effective November 10, 2026, Jørgensen will begin serving on Lundbeck's Board as an observer until formally elected during the AGM in 2027, pending shareholder approval. His vast experience encompasses global pharmaceutical strategy, innovation, and the commercialization of health solutions, making him a fitting choice for Lundbeck’s upcoming endeavors.
Lene Skole, Vice Chair of the Board, expressed gratitude towards Wenzel for her dedication, stating, "Dorothea's leadership has been pivotal during our transformative phase, including the recruitment of our new CEO in 2023 and the initiation of our Focused Innovator strategy. The progress Lundbeck has achieved places us in a much stronger position than just a few years prior, and as we look ahead, continuity in leadership is essential."
In her farewell remarks, Wenzel identified this transition as a timely decision as Lundbeck is positioned for growth. She remarked on the significant advancements made under her tenure, underscoring her pride in the Board’s collaborative efforts to fortify the company’s market standing. "It has been an honor and a privilege to serve at Lundbeck. As we gear up for the next phase, I am confident in the company’s direction and its capacity to build on the strong foundation we have established."
Looking forward, Jørgensen is optimistic about stepping into the Chair position, highlighting Lundbeck’s commitment to brain health paired with a robust business model and promising product pipeline. He shared his enthusiasm for working alongside the Board and executive leadership to further support Lundbeck’s aspirations, benefiting patients, employees, and shareholders alike.
As the 2027 AGM approaches, the nominated candidates for Board membership will be formally announced. Lundbeck is enthusiastic about its future under new leadership, striving to capitalize on its achievements while committed to enhancing global brain health solutions.
In sum, this leadership transition not only signals a continuity of vision but also a renewed commitment to Lundbeck’s strategic objectives and focus on improving lives impacted by neurological and psychiatric disorders. The company remains firmly dedicated to evolving its research, innovating care solutions, and enhancing health equity, with the aim to bring forth lasting value for all stakeholders involved.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.